| 23.53 -0.46 (-1.92%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.74 | 1-year : | 32.09 |
| Resists | First : | 25.46 | Second : | 27.47 |
| Pivot price | 24.34  |
|||
| Supports | First : | 22.2 | Second : | 18.47 |
| MAs | MA(5) : | 24.43 |
MA(20) : | 24.36 |
| MA(100) : | 20.74  |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 29.5 |
D(3) : | 38.4 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 27.47 | Low : | 13.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LBRX ] has closed above bottom band by 24.1%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.49 - 24.61 | 24.61 - 24.73 |
| Low: | 22.92 - 23.06 | 23.06 - 23.21 |
| Close: | 23.26 - 23.49 | 23.49 - 23.72 |
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Tue, 10 Mar 2026
LB Pharmaceuticals (LBRX) director receives 20,000 stock options vesting 2027–2029 - Stock Titan
Tue, 10 Mar 2026
LB Pharmaceuticals (Nasdaq: LBRX) names new director and COO - Stock Titan
Wed, 04 Mar 2026
LBRX SEC Filings - LB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 06 Feb 2026
LB Pharmaceuticals Announces $100 Million Private Placement Financing - The Globe and Mail
Thu, 05 Feb 2026
LB Pharmaceuticals lines up $100M for new depression trial - Stock Titan
Thu, 05 Feb 2026
LB Pharmaceuticals Announces $100.0 Million Private Placement - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 94.8 (%) |
| Shares Short | 2,200 (K) |
| Shares Short P.Month | 1,790 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -31.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|